Hepatology News

Financial independence is the holy grail, which affords one to work for the sake of working with the peace of mind of knowing they are no longer dependent on a paycheck to maintain their lifestyle.

Treatment of chronic hepatitis C virus with direct-acting antivirals improved liver-related morbidity and survival, regardless of hepatocellular carcinoma, although patients aged older than 60 years should be monitored, a presenter noted.

Treatment with efruxifermin resulted in significant improvement in fibrosis at week 24 in patients with metabolic dysfunction-associated steatohepatitis, which was “sustained and expanded through week 96,” according to late-breaking data.

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.

Although rifaximin was well-tolerated in patients with severe cirrhosis and ascites, it did not improve transplant-free survival and cirrhosis-related complications and “cannot be recommended” as antibiotic prophylaxis, a researcher noted.

Researchers identified bile duct dysplasia or cancer in most explanted livers with an indication of biliary dysplasia, although as many as 41% had no signs of neoplasia, according to a study of patients with primary sclerosing cholangitis.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reports that combination bulevirtide 10 mg with pegylated interferon alfa-2a for chronic hepatitis D virus infection resulted in the highest rates of undetectable HDV RNA through 48 weeks.

Denifanstat, a fatty acid synthase inhibitor, outperformed placebo in metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis and fibrosis improvement, according to data presented at EASL Congress.

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.

Recurrence of hepatic encephalopathy was lower among patients with cirrhosis and hepatic encephalopathy who received oral capsule or enema fecal microbiota transplant vs. placebo, according to research from EASL Congress.